Metronomic administration of topotecan alone and in combination with docetaxel inhibits epithelial-mesenchymal transition in aggressive variant prostate cancers
To identify molecular signatures and their potential to serve as novel biomarkers for monitoring treatment efficacy and disease progression response to treatment efficacy and disease progression Overall design: Effects of METRO-TOPO and CONV-TOPO exposure for six weeks on ARLow mCRPC/NEPC PC-3 tumor model (3D spheroid) were assessed using RNAseq.